New Production Lines In Lohr And Skopje Will Improve Efficiency

Key Takeaways

• The acquisition of Bormioli Pharma and new product lines are expected to significantly boost Gerresheimer's revenue and profitability.
  
• Strategic facility upgrades and a shift to high-value products aim to enhance margins and improve overall earnings.
  
• Potential integration risks from Bormioli Pharma acquisition and ongoing financial challenges could affect Gerresheimer's liquidity, margins, and operational stability.

Catalysts

Manufactures and sells medicine packaging, drug delivery devices, and solutions in Germany and internationally.

• The acquisition of Bormioli Pharma is expected to propel Gerresheimer's revenues from €2 billion in 2024 to around €2.5 billion in 2025, while also enhancing the company's adjusted EBITDA margin to approximately 22%. This marks a significant step forward in terms of revenue growth and profitability enhancement.
  
• The anticipated organic growth rate of 3% to 5% in 2025, driven by new product lines, a shift towards high-value products, and normalization of operations at facilities affected by prior disruptions, is poised to positively impact Gerresheimer's revenue and profitability.
  
• The ramping up of new production lines in Skopje and Peachtree City, and the introduction of advanced products such as ready-to-fill syringes and vials, indicates a move towards higher-margin products which is expected to improve net margins and earnings.
  
• The strategic transitions and capacity expansions at key facilities like the new state-of-the-art hybrid furnace in Lohr, and the restoration of full capacity at Morganton, are likely to enhance production efficiency and contribute positively to future earnings.
  
• The ongoing trend towards high-value product offerings, such as the shift from standard bulk vials to high-value vials, is positioned to strengthen net margins and improve overall earnings due to superior pricing and market demand for innovative solutions.

Gerresheimer Future Earnings and Revenue Growth

Assumptions

• Analysts are assuming Gerresheimer's revenue will grow by 12.4% annually over the next 3 years.
• Analysts assume that profit margins will increase from 3.8% today to 7.7% in 3 years time.
• Analysts expect earnings to reach €229.8 million (and earnings per share of €6.61) by about April 2028, up from €78.7 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting €325.1 million in earnings, and the most bearish expecting €178 million.
• In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 17.2x on those 2028 earnings, down from 23.4x today. This future PE is lower than the current PE for the GB Life Sciences industry at 26.5x.
• Analysts expect the number of shares outstanding to remain consistent over the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.37%, as per the Simply Wall St company report.

Gerresheimer Future Earnings Per Share Growth

Risks

• The integration of Bormioli Pharma presents potential integration risks and associated costs, which could impact overall operational efficiency and margins.
  
• There is significant seasonal fluctuation in cash flow, with Q1 often showing negative free cash flow figures, which could stress liquidity and financial stability if not managed prudently.
  
• Ongoing challenges in the moulded glass sector, including decreased demand in the cosmetics market, could negatively impact revenues and operational stability in the short term.
  
• The company's increased leverage due to the acquisition of Bormioli could, if not carefully managed, lead to financial strain, impacting earnings and investor confidence.
  
• Delays and disruptions, such as those from natural disasters affecting Morganton, could introduce further operational risks, impacting revenue streams and margins.

Valuation

• The analysts have a consensus price target of €93.667 for Gerresheimer based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of €122.5, and the most bearish reporting a price target of just €68.0.
• In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be €3.0 billion, earnings will come to €229.8 million, and it would be trading on a PE ratio of 17.2x, assuming you use a discount rate of 7.4%.
• Given the current share price of €53.4, the analyst price target of €93.67 is 43.0% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.